CryoPort (NASDAQ:CYRX) Stock Price Breaks Above 50 Day Moving Average on Disappointing Earnings

Key Points

• CryoPort’s quarterly revenue rose 14% year over year to $50.22 million, beating estimates, and the company raised its 2026 revenue outlook to $197 million–$199 million.
• The company reported a loss of $0.25 per share, worse than the expected $0.18 loss and wider than its loss a year earlier.
• Shares climbed 19% and moved above their 50-day moving average; analysts cited in the article generally rated the stock positively, with an average price target of $21.69.

CryoPort, Inc. (NASDAQ:CYRX - Get Free Report)'s share price passed above its 50 day moving average during trading on Friday after the company announced better than expected quarterly earnings. The stock has a 50 day moving average of $16.98 and traded as high as $19.53. CryoPort shares last traded at $19.10, with a volume of 2,585,565 shares.

The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.07). The firm had revenue of $50.22 million for the quarter, compared to the consensus estimate of $48.66 million. CryoPort had a negative return on equity of 7.20% and a negative net margin of 20.05%.

CryoPort News Summary

Here are the key news stories impacting CryoPort this week:

• Positive Sentiment: Third-quarter revenue rose 14% year over year to $50.2 million, topping estimates of $48.66 million. Commercial cell and gene therapy revenue grew 20%; Cryoport supported a record 788 global clinical trials and 23 commercially approved therapies. Cryoport Reports Third Quarter 2026 Financial Results
• Positive Sentiment: The company raised its full-year 2026 revenue outlook to $197 million–$199 million, a key catalyst behind the favorable reaction to results. CryoPort Shares Rise After Q3 Revenue Beat, 2026 Guidance Raise
• Positive Sentiment: Analyst actions added support: Needham raised its price target to $28 from $19 and reiterated Buy, while KeyCorp lifted its target to $20 from $17 and maintained an Overweight rating. Needham Adjusts Price Target KeyCorp Rating
• Negative Sentiment: Adjusted earnings were a loss of $0.25 per share, missing consensus estimates of a $0.18–$0.19 loss and widening from a $0.18 loss a year earlier. The earnings shortfall may temper optimism around the revenue growth and raised outlook. CryoPort Reports Q3 Loss, Tops Revenue Estimates

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Guggenheim lifted their target price on shares of CryoPort from $16.00 to $19.00 and gave the stock a "buy" rating in a report on Thursday, October 1st. BTIG Research upped their price target on shares of CryoPort from $25.00 to $26.00 and gave the company a "buy" rating in a research note on Tuesday, October 13th. Needham & Company LLC lifted their price target on shares of CryoPort from $19.00 to $28.00 and gave the stock a "buy" rating in a report on Friday. Robert W. Baird set a $26.00 price target on CryoPort in a research note on Tuesday, October 13th. Finally, Weiss Ratings upgraded shares of CryoPort from a "sell (d)" rating to a "hold (c-)" rating in a research report on Thursday, October 8th. Seven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $21.69.

Insider Buying and Selling at CryoPort

In other CryoPort news, CEO Jerrell Shelton sold 28,800 shares of the stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $14.91, for a total transaction of $429,408.00. Following the completion of the transaction, the chief executive officer owned 1,201,814 shares of the company's stock, valued at $17,919,046.74. This represents a 2.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.50% of the stock is currently owned by insiders.

Institutional Trading of CryoPort

Hedge funds and other institutional investors have recently bought and sold shares of the stock. State of Alaska Department of Revenue purchased a new stake in CryoPort during the 3rd quarter worth approximately $40,000. State of Wyoming boosted its stake in shares of CryoPort by 9.4% in the first quarter. State of Wyoming now owns 42,520 shares of the company's stock valued at $352,000 after purchasing an additional 3,638 shares during the period. Headlands Technologies LLC boosted its position in shares of CryoPort by 14.5% during the 2nd quarter. Headlands Technologies LLC now owns 38,742 shares of the company's stock worth $608,000 after acquiring an additional 4,906 shares in the last quarter. Quantinno Capital Management LP raised its position in CryoPort by 30.7% in the 1st quarter. Quantinno Capital Management LP now owns 43,966 shares of the company's stock valued at $364,000 after purchasing an additional 10,337 shares during the last quarter. Finally, Counterpoint Mutual Funds LLC acquired a new position in CryoPort in the 3rd quarter valued at $324,000. Institutional investors own 92.90% of the company's stock.

CryoPort Stock Up 19.0%

The firm has a fifty day moving average of $16.98 and a 200-day moving average of $13.46. The stock has a market capitalization of $967.42 million, a price-to-earnings ratio of -19.69 and a beta of 1.89.

About CryoPort

CryoPort, Inc NASDAQ: CYRX provides temperature-controlled supply chain solutions for the life sciences industry. The company supports the transportation, storage and management of biological materials, including cell and gene therapies, vaccines, biologics, reproductive materials and other temperature-sensitive products.

Its offerings include cryogenic and refrigerated shipping containers, biological material storage, transportation logistics, shipment monitoring and related supply chain management services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.